miR-31-5p as a Potential Circulating Biomarker and Tracer of Clinical Improvement for Chronic Inflammatory Demyelinating Polyneuropathy

Table 1

The clinical characteristics of patients without and with diabetes.

		Group of patients without diabetes		Group of patients with diabetes		value
		Mean	SD	Mean	SD
miR-31-5p/100 μl of serum		1366.33	2054.54	1146.97	1953.03	0.332
Duration of the CIDP (years)		5.35	3.07	5.24	3.42	0.688
Duration of IgIV treatment (months)		17.16	13.01	12.00	14.90	0.076
Body weight (kg)		87.32	20.27	90.24	20.12	0.726
INCAT upper limbs		1.94	1.00	1.12	0.70	0.005
INCAT lower limbs		1.97	1.17	1.41	0.80	0.086
Serum	CK (IU/l)	279.13	197.57	250.59	194.48	0.698
Cerebrospinal fluid	IgG (g/l)	10.95	2.87	10.55	1.86	0846
	IgA (g/l)	2.29	0.86	2.65	1.28	0.532
	IgM; (g/l)	1.18	0.83	0.87	0.63	0.200
	Pleocytosis (cells/μl)	3.43	2.49	4.18	3.70	0.796
	Protein (mg/dl)	72.39	37.20	7741	30.66	0.499
Age (years)		59.23	11.93	65.94	10.40	0.070
ni			31		17
Gender

Abbreviation: ni: number of patients in the group.